Pub Date : 2022-06-24DOI: 10.25073/2588-1132/vnumps.4399
Tran Thi Van Anh, P. D. Tuan, N. Khánh, Dao Viet Hung, N. Hai, N. Q. Tuan, N. Diep, Ngo Thi Xuan Thinh, Ha Thanh Hoa
Kirenol (1), darutoside (2), and darutigenol (3), which are major active diterpenoids isolated from Herba Siegesbeckiae, are reported for analgesic activity and inflammatory effects. Currently, in Vietnamese Pharmacopoeia V, there is no requirement for the contents of active ingredients in this medicinal plant. In this study, a high-performance liquid chromatography (HPLC) method, which was developed with good repeatability and recovery, was used for simultaneous quantification of 1, 2, and 3 in Herba Siegesbeckiae. This method was successfully applied to quantify 1-3 in samples of Herba Siegesbeckiae collected from different locations. The results showed that the content of compound 1 accounted for 0 – 5.77 mg/g, compound 2 ranged from 0.82 to 5.48 mg/g, and compound 3 ranged from 0.37 to 3.18 mg/g. These results are considered a reference for upgrading the specification and quality control of Herba Siegesbeckiae. Keywords: Herba Siegesbeckiae; kirenol; darutoside; darutigenol; HPLC.
{"title":"Simultaneous Quantification of Kirenol, Daurutoside, and Darutigenol in Siegesbeckia orientalis L. by HLPC-DPA Method","authors":"Tran Thi Van Anh, P. D. Tuan, N. Khánh, Dao Viet Hung, N. Hai, N. Q. Tuan, N. Diep, Ngo Thi Xuan Thinh, Ha Thanh Hoa","doi":"10.25073/2588-1132/vnumps.4399","DOIUrl":"https://doi.org/10.25073/2588-1132/vnumps.4399","url":null,"abstract":"Kirenol (1), darutoside (2), and darutigenol (3), which are major active diterpenoids isolated from Herba Siegesbeckiae, are reported for analgesic activity and inflammatory effects. Currently, in Vietnamese Pharmacopoeia V, there is no requirement for the contents of active ingredients in this medicinal plant. In this study, a high-performance liquid chromatography (HPLC) method, which was developed with good repeatability and recovery, was used for simultaneous quantification of 1, 2, and 3 in Herba Siegesbeckiae. This method was successfully applied to quantify 1-3 in samples of Herba Siegesbeckiae collected from different locations. The results showed that the content of compound 1 accounted for 0 – 5.77 mg/g, compound 2 ranged from 0.82 to 5.48 mg/g, and compound 3 ranged from 0.37 to 3.18 mg/g. These results are considered a reference for upgrading the specification and quality control of Herba Siegesbeckiae. \u0000Keywords: \u0000Herba Siegesbeckiae; kirenol; darutoside; darutigenol; HPLC. \u0000 \u0000 ","PeriodicalId":23520,"journal":{"name":"VNU Journal of Science: Medical and Pharmaceutical Sciences","volume":"49 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80828597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-06-24DOI: 10.25073/2588-1132/vnumps.4407
Pham Thi Minh Ngoc, Nguyễn Văn Sơn
Study on 41 patients with anterior cruciate ligament rupture diagnosed and treated at E Hospital from March 2021 to April 2022 showed: Mean age: 36.02, Male: 68.3%, female: 27.7%. Traffic accidents: 65.9%. Right foot: 53.7%, left foot: 44.3%. Timefrom injury to treatment > 3 weeks: 70.7%. Clinical: loose knee: 90.2%; pain: 87.8%; difficulty going up and down stairs: 65.9%; knee swelling: 51.2%; effusion: 68.3%; front drawer: 95.1%; Lachman: 92.7%; McMurray: 41.4%; average Lysholm score: 60.88. Magnetic resonance imaging (MRI): decompression/intermittent: complete: 52.7%, partial: 46.3%; contusion, edema: 41.5%; hematoma-hemorrhage: 87.7%; bone marrow edema: 34.1%; meniscus tear: 46.3%. Treatment results: pain relief upon discharge: 70.7%; incision: dry: 56.1% drainage: 43.9%, infection: 0, after follow-up: mean Lysholm score: 86.95, complications: numbness, burning behind the thigh: 2.44%.
{"title":"Characteristics of Clinical and Magnetic Resonance, and Treatment Result for Anterior Cruciate Ligament Tear of the Knee Joint","authors":"Pham Thi Minh Ngoc, Nguyễn Văn Sơn","doi":"10.25073/2588-1132/vnumps.4407","DOIUrl":"https://doi.org/10.25073/2588-1132/vnumps.4407","url":null,"abstract":"Study on 41 patients with anterior cruciate ligament rupture diagnosed and treated at E Hospital from March 2021 to April 2022 showed: Mean age: 36.02, Male: 68.3%, female: 27.7%. Traffic accidents: 65.9%. Right foot: 53.7%, left foot: 44.3%. Timefrom injury to treatment > 3 weeks: 70.7%. Clinical: loose knee: 90.2%; pain: 87.8%; difficulty going up and down stairs: 65.9%; knee swelling: 51.2%; effusion: 68.3%; front drawer: 95.1%; Lachman: 92.7%; McMurray: 41.4%; average Lysholm score: 60.88. Magnetic resonance imaging (MRI): decompression/intermittent: complete: 52.7%, partial: 46.3%; contusion, edema: 41.5%; hematoma-hemorrhage: 87.7%; bone marrow edema: 34.1%; meniscus tear: 46.3%. Treatment results: pain relief upon discharge: 70.7%; incision: dry: 56.1% drainage: 43.9%, infection: 0, after follow-up: mean Lysholm score: 86.95, complications: numbness, burning behind the thigh: 2.44%.","PeriodicalId":23520,"journal":{"name":"VNU Journal of Science: Medical and Pharmaceutical Sciences","volume":"25 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81438201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-06-24DOI: 10.25073/2588-1132/vnumps.4393
Dang Thi Thuy Ngan, Ha Thi Thanh Huong, Pham Thi Thu Thao, Nguyễn Thanh Hải, N. H. Hai Yen, Bùi Thị Thương, N. T. Hiền
Essential oil from Citrus maxima was extracted by steam distillation and solvent extraction. The organic solvent extraction method achieved a 28.5% increase in efficiency compared with the steam distillation method. TD1 essential oil had a strong smell, mixed with water and other impurities (wax, resin...). In contrast, TD2 essential oil was fragrant due to its high essential oil content. The chemical composition of TD2 was more than TD1. The main components of essential oils such as pinene, limonene, phellandrene, ocimene, linalool, anethole, eugenol, zingiberene, nerolidol, etc. were kept intact, not denatured, without impurities. Keywords: Citrus maxima, Oil, steam distillation, solvent extraction, GC-MS.
{"title":"Evaluation of Two Methods of Extracting Essential Oils from Citrus maxima","authors":"Dang Thi Thuy Ngan, Ha Thi Thanh Huong, Pham Thi Thu Thao, Nguyễn Thanh Hải, N. H. Hai Yen, Bùi Thị Thương, N. T. Hiền","doi":"10.25073/2588-1132/vnumps.4393","DOIUrl":"https://doi.org/10.25073/2588-1132/vnumps.4393","url":null,"abstract":"Essential oil from Citrus maxima was extracted by steam distillation and solvent extraction. The organic solvent extraction method achieved a 28.5% increase in efficiency compared with the steam distillation method. TD1 essential oil had a strong smell, mixed with water and other impurities (wax, resin...). In contrast, TD2 essential oil was fragrant due to its high essential oil content. The chemical composition of TD2 was more than TD1. The main components of essential oils such as pinene, limonene, phellandrene, ocimene, linalool, anethole, eugenol, zingiberene, nerolidol, etc. were kept intact, not denatured, without impurities. \u0000Keywords: \u0000Citrus maxima, Oil, steam distillation, solvent extraction, GC-MS.","PeriodicalId":23520,"journal":{"name":"VNU Journal of Science: Medical and Pharmaceutical Sciences","volume":"40 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91374076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-06-24DOI: 10.25073/2588-1132/vnumps.4384
D. Ngoc, Le My Hanh, Pham Quang Huy, Phung Hai Nam
Objectives: This study was done to describe the imaging characteristics of acute appendicitis on multislice computed tomography (MSCT) and the value of MSCT scan in the diagnosis of acute appendicitis. Methods: The study used retrospective and cross-sectional methods to analyze the results of 117 patients who were taken photos of CT at E Hospital from February 2021 to November 2021. Results: The most common age was over 50 years old, and the average age was 40.1±20.8. The ratio of male/female was 1/1.25. Locations of appendix: right iliac fossa 69.2%, posterior cecum 16.2%, pelvis 12%, subhepatic 0.9%, 1.7% in other places in the abdomen. The diameter of appendicitis was 10.48±2.5mm (the min was 5mm, the max was 18mm). The increase of diameter over 7mm accounted for 95.7%, appendiceal wall thickness ≥ 3mm had 83.8% of patients, and fat infiltration was seen in 88% of cases studied. Other signs: fecal stones 35%, fluid around appendix 7.7%, Douglas fluid 3.4%, right iliac fossa fluid 3.4%, mesenteric lymphadenopathy 25.7%. The rate of appendix rupture diagnosed by CT accounted was 4.3%. The sensitivity, accuracy, and positive diagnostic value of multislice CT in the diagnosis of acute appendicitis were 97.4%, 96.6%, and 99.1%, respectively. Conclusion: Multislice CT has a high value in the diagnosis of acute appendicitis.
{"title":"Imaging Characteristics and Value of Multislice Computed Tomography in the Diagnosis of Acute Appendicitis","authors":"D. Ngoc, Le My Hanh, Pham Quang Huy, Phung Hai Nam","doi":"10.25073/2588-1132/vnumps.4384","DOIUrl":"https://doi.org/10.25073/2588-1132/vnumps.4384","url":null,"abstract":"Objectives: This study was done to describe the imaging characteristics of acute appendicitis on multislice computed tomography (MSCT) and the value of MSCT scan in the diagnosis of acute appendicitis. Methods: The study used retrospective and cross-sectional methods to analyze the results of 117 patients who were taken photos of CT at E Hospital from February 2021 to November 2021. Results: The most common age was over 50 years old, and the average age was 40.1±20.8. The ratio of male/female was 1/1.25. Locations of appendix: right iliac fossa 69.2%, posterior cecum 16.2%, pelvis 12%, subhepatic 0.9%, 1.7% in other places in the abdomen. The diameter of appendicitis was 10.48±2.5mm (the min was 5mm, the max was 18mm). The increase of diameter over 7mm accounted for 95.7%, appendiceal wall thickness ≥ 3mm had 83.8% of patients, and fat infiltration was seen in 88% of cases studied. Other signs: fecal stones 35%, fluid around appendix 7.7%, Douglas fluid 3.4%, right iliac fossa fluid 3.4%, mesenteric lymphadenopathy 25.7%. The rate of appendix rupture diagnosed by CT accounted was 4.3%. The sensitivity, accuracy, and positive diagnostic value of multislice CT in the diagnosis of acute appendicitis were 97.4%, 96.6%, and 99.1%, respectively. Conclusion: Multislice CT has a high value in the diagnosis of acute appendicitis.","PeriodicalId":23520,"journal":{"name":"VNU Journal of Science: Medical and Pharmaceutical Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86357670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-06-24DOI: 10.25073/2588-1132/vnumps.4374
Tran Trong Bien, Tran Mai Thi Tuyet, Bui Thi Lan Phuong, Pham Thai Ha Van
Herbal extracts are one of the herbal preparations obtained by the extraction method. There has been an increasing trend of application of herbal extracts to replace traditional medicinal herbs in using and manufacturing of drug dosage forms. The quality characteristics of herbal extracts roots from their multi-components nature, leading to multiple targets and mechanisms of action. Thus hindering the development of quality assessment systems and also the application of pharmaceutical technologies in the development of modern dosage forms, leading to a decrease in therapeutic efficacy in clinical practice. This review systematizes some information related to herbal extracts: the position and importance of herbal extracts in drug research and development, classification, characteristics, and quality control strategies. The purpose of this review is to consolidate and expand the general understanding of the “pharmaceutical nature” of herbal extracts and to provide some quality control strategies using markers and reference materials Keywords Herbal extracts, quality characteristics, classification, quality control, pharmaceutical nature.
{"title":"Herbal Extracts: Importance, Classification, Quality Characteristics, and Control","authors":"Tran Trong Bien, Tran Mai Thi Tuyet, Bui Thi Lan Phuong, Pham Thai Ha Van","doi":"10.25073/2588-1132/vnumps.4374","DOIUrl":"https://doi.org/10.25073/2588-1132/vnumps.4374","url":null,"abstract":"Herbal extracts are one of the herbal preparations obtained by the extraction method. There has been an increasing trend of application of herbal extracts to replace traditional medicinal herbs in using and manufacturing of drug dosage forms. The quality characteristics of herbal extracts roots from their multi-components nature, leading to multiple targets and mechanisms of action. Thus hindering the development of quality assessment systems and also the application of pharmaceutical technologies in the development of modern dosage forms, leading to a decrease in therapeutic efficacy in clinical practice. This review systematizes some information related to herbal extracts: the position and importance of herbal extracts in drug research and development, classification, characteristics, and quality control strategies. The purpose of this review is to consolidate and expand the general understanding of the “pharmaceutical nature” of herbal extracts and to provide some quality control strategies using markers and reference materials \u0000Keywords \u0000Herbal extracts, quality characteristics, classification, quality control, pharmaceutical nature.","PeriodicalId":23520,"journal":{"name":"VNU Journal of Science: Medical and Pharmaceutical Sciences","volume":"39 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81481591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-06-24DOI: 10.25073/2588-1132/vnumps.4347
Nguyen Thi Quynh Mai, Nguyen Le Trung Hieu, Le Thi Khanh Van, Nguyen Thuy Minh Thu, Le Tran Anh Ngan, Huynh Thi Dieu Hien, Do Thi Thu Hang
Ohtahara syndrome is one of the earliest and most severe forms of developmental and epileptic encephalopathy. Over the last decade, the rapid advances in molecular techniques, especially in high-throughput sequencing (HTS), have revealed that a majority of Ohtahara patients have genetic etiology. About 20 genes have been found to be related to this syndrome so far, and Next Generation Sequencing (NGS) technique is now an important genetic test for this syndrome. This study was conducted on 4 patients with Ohtahara syndrome referred to Children’s Hospital 2, Ho Chi Minh City. Whole-exome sequencing (WES) following targeted analysis on 283 epileptic encephalopathy–related genes was performed to identify disease-causing variants of the patients. Following multi-step bioinformatics analysis, trio-based Sanger sequencing confirmation, and variant classification according to standards of The American College of Medical Genetics and Genomics – 2015, we have identified 2 pathogenic mutations in 2 patients: OH3 (KCNQ2, c.868G>A, p.G290S) and OH4 (SCN2A, c.788C>T, p.A263V). The results of this study contribute to verifying the role of genetic factors in Ohtahara syndrome in Vietnamese patients. This study also confirms that NGS in general and WES, in particular, are reliable and useful in detecting genetic causes of Ohtahara syndrome, thereby, assisting in diagnosis and treatment of this syndrome.
{"title":"Application of Whole Exome Sequencing in Mutational Analysis of Patients with Ohtahara Syndrome","authors":"Nguyen Thi Quynh Mai, Nguyen Le Trung Hieu, Le Thi Khanh Van, Nguyen Thuy Minh Thu, Le Tran Anh Ngan, Huynh Thi Dieu Hien, Do Thi Thu Hang","doi":"10.25073/2588-1132/vnumps.4347","DOIUrl":"https://doi.org/10.25073/2588-1132/vnumps.4347","url":null,"abstract":"Ohtahara syndrome is one of the earliest and most severe forms of developmental and epileptic encephalopathy. Over the last decade, the rapid advances in molecular techniques, especially in high-throughput sequencing (HTS), have revealed that a majority of Ohtahara patients have genetic etiology. About 20 genes have been found to be related to this syndrome so far, and Next Generation Sequencing (NGS) technique is now an important genetic test for this syndrome. This study was conducted on 4 patients with Ohtahara syndrome referred to Children’s Hospital 2, Ho Chi Minh City. Whole-exome sequencing (WES) following targeted analysis on 283 epileptic encephalopathy–related genes was performed to identify disease-causing variants of the patients. Following multi-step bioinformatics analysis, trio-based Sanger sequencing confirmation, and variant classification according to standards of The American College of Medical Genetics and Genomics – 2015, we have identified 2 pathogenic mutations in 2 patients: OH3 (KCNQ2, c.868G>A, p.G290S) and OH4 (SCN2A, c.788C>T, p.A263V). The results of this study contribute to verifying the role of genetic factors in Ohtahara syndrome in Vietnamese patients. This study also confirms that NGS in general and WES, in particular, are reliable and useful in detecting genetic causes of Ohtahara syndrome, thereby, assisting in diagnosis and treatment of this syndrome. \u0000 \u0000 \u0000 \u0000 \u0000 \u0000","PeriodicalId":23520,"journal":{"name":"VNU Journal of Science: Medical and Pharmaceutical Sciences","volume":"56 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89876495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-06-24DOI: 10.25073/2588-1132/vnumps.4348
Nguyen Thi Kim Dung, Chu Van Thang
Research objective: describe the current situation and some factors related to injury accidents of children under 5 years old in 3 communes of Hoai Duc district, Hanoi city 2020. Objects and research methods: A cross-sectional descriptive study on 901 families with children under 5 years old in 3 communes of Hoai Duc district, Hanoi city in 2020. Research results: About the situation: The rate of accidents and injuries is 14.77%. Most of the injuries in 2-year-olds accounted for 40.53%. The leading causes are: Fall/fall (41.05%); sharp objects (14.74%) and burns (12.63%). The most common time for children to have accidents and injuries is from 6 am to 12 am (45.79%) and 12 to 18 pm (34.74%). Accidents and injuries are unintentionally caused by children themselves, accounting for 62.11%. 97.4% of children received first aid within 30 minutes of the accident. Regarding the relationship: Male caregivers are 1.46 times more likely to cause injury to children than female caregivers. Caregivers of children who have completed university/college/secondary education are 8.85 times less likely to cause their children to suffer from an accident than people who do not attend school (OR: 8.85, 95%CI: 1.92) – 40.88). Male children have 1.47 times higher risk of having a stroke than girls (OR: 1.47, 95% CI: 1.08 – 2.00), the relationship is statistically significant with p < 0.05. Conclusion: The rate of accidents and injuries is still quite high at 14.77%, most of the children have self-inflicted injuries at a time when there are few caregivers at home. Education level, caregiver's gender, and child's gender are related to the risk of injury.
{"title":"Situation and some Factors Related to Injury of Children Under 5 Years Old in 3 Communes of Hoai Duc District, Hanoi City in 2020","authors":"Nguyen Thi Kim Dung, Chu Van Thang","doi":"10.25073/2588-1132/vnumps.4348","DOIUrl":"https://doi.org/10.25073/2588-1132/vnumps.4348","url":null,"abstract":"Research objective: describe the current situation and some factors related to injury accidents of children under 5 years old in 3 communes of Hoai Duc district, Hanoi city 2020. Objects and research methods: A cross-sectional descriptive study on 901 families with children under 5 years old in 3 communes of Hoai Duc district, Hanoi city in 2020. Research results: About the situation: The rate of accidents and injuries is 14.77%. Most of the injuries in 2-year-olds accounted for 40.53%. The leading causes are: Fall/fall (41.05%); sharp objects (14.74%) and burns (12.63%). The most common time for children to have accidents and injuries is from 6 am to 12 am (45.79%) and 12 to 18 pm (34.74%). Accidents and injuries are unintentionally caused by children themselves, accounting for 62.11%. 97.4% of children received first aid within 30 minutes of the accident. Regarding the relationship: Male caregivers are 1.46 times more likely to cause injury to children than female caregivers. Caregivers of children who have completed university/college/secondary education are 8.85 times less likely to cause their children to suffer from an accident than people who do not attend school (OR: 8.85, 95%CI: 1.92) – 40.88). Male children have 1.47 times higher risk of having a stroke than girls (OR: 1.47, 95% CI: 1.08 – 2.00), the relationship is statistically significant with p < 0.05. Conclusion: The rate of accidents and injuries is still quite high at 14.77%, most of the children have self-inflicted injuries at a time when there are few caregivers at home. Education level, caregiver's gender, and child's gender are related to the risk of injury.","PeriodicalId":23520,"journal":{"name":"VNU Journal of Science: Medical and Pharmaceutical Sciences","volume":"13 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84548595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-06-23DOI: 10.25073/2588-1132/vnumps.4377
Nguyen Doan Duy Linh, Pham Huy Tuan Kiet, Dang Thi Hon, Tran Tien Dat, Nguyen Xuan Bach
Objective: Epilepsy is a chronic non-communicable disease that can affect all ages, genders, races, and social classes with large treatment costs that vary widely between countries and regions. Perampanel is a new generation of antiepileptic drugs (AEDs), but cost-effectiveness reports are inconsistent in several countries that have conducted pharmacoeconomic evaluations. Study with the objective of systematically summarizing the evidence on the cost-effectiveness of Perampanel for the treatment of epilepsy. Methods: An exhaustive search was performed in four publication databases. Evaluation of the reporting quality of the studies using the CHEERS checklist. Results: Findings: Costs were lower in the Perampanel group than in the Lacosamide group (Perampanel 8mg/day vs. Lacosamide 400mg/day - Total cost: $2390 (12.89%), but higher than in the antiepilepsy drugs group without perampanel (Total Direct Cost: 5475 Euro and Total Indirect Cost: -5288 Euro, Total Cost: 188 Euro) and the group with recent add-on regime such as Brivaracetam (3188 Euro in total). When compared with the Lacosamide group, the Perampanel group showed increased outcomes in all three outcomes (convulsions, LY, and QALY). Similarly, the Perampanel group showed increased outcomes in all three outcomes (convulsions, LY, and QALY) compared with groups without Perampanel. Meanwhile, QALY in the Perampanel group was lower than in the Brivaracetam group (total of 0.059 QALY). Conclusions: Perampanel as an adjunct therapy for antiepilepsy drugs may be a cost-effective treatment option in the management of epilepsy. Keywords: Fycompa, perampanel, seizure, epilepsy, systematic review, cost-effective. References [1] R. S. Fisher, C. Acevedo, A. Arzimanoglou, A. Bogacz, J. H. Cross, C. E. Elger et al., ILAE Official Report: a Practical Clinical Definition of Epilepsy. Epilepsia, Vol. 55, No. 4, 2014, pp. 475-482.[2] K. M. Fiest, K. M. Sauro, S. Wiebe, S. B. Patten, C. S. Kwon, J. Dykeman, et al., Prevalence and Incidence of Epilepsy: A Systematic Review and Meta-analysis of International Studies, Neurology, Vol. 88, No. 3, 2017, pp. 296-303.[3] A. C. Meyer, T. Dua, J. Ma, S. Saxena, G. Birbeck, Global Disparities in The epilepsy Treatment Gap: a Systematic Review, Bull World Health Organ, Vol. 88, No. 4, 2010, pp. 260-266.[4] GBD, Neurology Collaborators, Global, Regional, and National Burden of Neurological Disorders, 1990-2016: a Systematic Analysis for the Global Burden of Disease Study 2016, Lancet Neurol, Vol. 18, No. 5, 2019, pp. 459-480.[5] S. Y. Chen, N. Wu, L. Boulanger, P. Sacco, Antiepileptic Drug Treatment Patterns and Economic Burden of Commercially-insured Patients with Refractory Epilepsy with Partial Onset Seizures in the United States, J Med Econ, Vol. 16, No. 2, 2013, pp. 240-248.[6] J. A. Cramer, Z. J. Wang, E. Chang, A. Powers, R. Copher, D. Cherepanov et al., Healthcare Utilization and Costs in Adults with Stable and Uncontrolled Epilepsy, Epilepsy Behav, Vol. 31,
目的:癫痫是一种慢性非传染性疾病，可影响所有年龄、性别、种族和社会阶层，不同国家和地区之间的治疗费用差异很大。Perampanel是新一代抗癫痫药物(aed)，但在进行药物经济学评估的几个国家中，成本效益报告不一致。研究目的是系统地总结Perampanel治疗癫痫的成本效益证据。方法:在四个出版数据库中进行穷举检索。使用CHEERS检查表评估研究报告的质量。结果:Perampanel组的成本低于Lacosamide组(Perampanel 8mg/天vs Lacosamide 400mg/天-总成本:2390美元(12.89%)，但高于不使用Perampanel的抗癫痫药物组(总直接成本:5475欧元，总间接成本:-5288欧元，总成本:188欧元)和最近添加布伐西坦(总成本3188欧元)的组。与拉科沙胺组相比，Perampanel组在所有三个结局(惊厥、LY和QALY)中都显示出增加的结果。同样，与没有使用Perampanel的组相比，Perampanel组在所有三个结局(惊厥、LY和QALY)中均显示出增加的结果。同时，Perampanel组的QALY低于布伐西坦组(共0.059 QALY)。结论:Perampanel作为抗癫痫药物的辅助治疗可能是一种具有成本效益的癫痫治疗选择。关键词:Fycompa, perampanel，癫痫发作，癫痫，系统评价，性价比。参考文献[10]R. S. Fisher, C. Acevedo, a . Arzimanoglou, a . Bogacz, J. H. Cross, C. E. Elger等，ILAE官方报告:癫痫的实用临床定义。《癫痫学》，2014年第55卷第4期，第475-482页王晓明，王晓明，王晓明，王晓明，等。癫痫患病率与发病率:国际研究的系统回顾与荟萃分析，中国神经病学杂志，2017，第3期，第296-303页a . C. Meyer, T. Dua, J. Ma, S. Saxena, G. Birbeck，癫痫治疗差距的全球差异:系统评价，世界卫生杂志，Vol. 88, No. 4, 2010, pp. 260-266GBD，神经病学合作者，全球，地区和国家神经系统疾病负担，1990-2016:全球疾病负担研究2016的系统分析，柳叶刀神经科学，Vol. 18, No. 5, 2019, pp. 459-480陈淑艳，吴宁，陈淑艳，沈鹏。美国商业保险难治性癫痫部分性发作患者的抗癫痫药物治疗模式与经济负担，医学经济杂志，Vol. 16, No. 2, 2013, pp. 240-248J. A. Cramer，王正杰，张e .， A. Powers, R. Copher, D. Cherepanov等，稳定型和非控制型癫痫成人的医疗保健利用与成本，癫痫行为，Vol. 31, 2014, pp. 356-362K. Allers, B. M. Essue, M. L. Hackett, J. Muhunthan, C. S. Anderson, K. Pickles等，癫痫的经济影响:系统评价，中华医学会神经病学杂志，2015年第15卷，第245页徐德良，云南省社区抗癫痫药物使用评价[硕士论文]，越南，河内，河内药学院，2010(越南文)Hoan N. C.， Muoi H. D.， 5 ~ 15岁儿童重度全身性癫痫的临床特征。实用医学杂志，第860卷，第3期，2013,pp. 48-50(越南文)国家健康和临床卓越研究所，癫痫:初级和二级保健成人和儿童癫痫的诊断和管理:临床指南药理学更新20，伦敦，2012who - ofs - e，癫痫:医师手册，2004. bbb . 10G. Tremblay, D. Howard, W. Tsong, V. Patel, J. D. Rosendo, Perampanel治疗原发性全身性强直-阵挛性发作(PGTCS)的成本效益:西班牙视角，癫痫与行为，E&B, Vol. 86, 2018;108 - 115页。[13]张晓明，张晓明，张晓明，等。综合卫生经济评估报告标准(CHEERS)，中国医学杂志，2013年第3期，第1 - 4页张丹，李晓霞，丁静，柯晓霞，丁伟，任勇，等。Perampanel在癫痫部分发作性发作辅助治疗中的价值:成本-效果和预算影响分析，中国医学杂志，2013,no . 9, pp. 866S. Väätäinen, E. Soini, J. Peltola, M. Charokopou, M. Taiha, R. Kälviäinen，芬兰局灶性癫痫发作辅助布瓦西坦治疗策略的经济价值，治疗进展，Vol. 37, No. 1, 2020, pp. 477-500H. M. Hamer, a . Spottke, C. Aletsee, S. Knake, J. Reis, a . Strzelczyk等人，德国三级癫痫中心难治性癫痫的直接和间接成本，《癫痫》，第47卷，第12期，2006年，页。 2165 - 2172。[17]高丽丽，夏丽丽，潘树清，熊涛，李世昌，基于疾病成本的癫痫直接、间接和无形成本研究，中国医学杂志，2015,pp. 146-156陈晓明，陈晓明，陈晓明，陈晓明等。骨质疏松和骨性关节炎的临床与经济评估:来自欧洲骨质疏松和骨性关节炎临床与经济方面的专家共识文章(ESCEO)，论文发表于2014年中国风湿病与风湿病学术研讨会陈晓明，陈晓明，陈晓明，陈晓明等。骨质疏松与骨性关节炎的临床与经济研究进展:基于临床与经济研究的研究报告，中国医学工程学报，2013,31 (4):555 - 557王晓明，张晓明，《部分发作性癫痫治疗的成本-效果:文献综述》，《医药经济》，2012年第10期，第903-923页。
{"title":"A Systematic Review of the Cost-effectiveness of Perampanel in the Treatment of Epilepsy","authors":"Nguyen Doan Duy Linh, Pham Huy Tuan Kiet, Dang Thi Hon, Tran Tien Dat, Nguyen Xuan Bach","doi":"10.25073/2588-1132/vnumps.4377","DOIUrl":"https://doi.org/10.25073/2588-1132/vnumps.4377","url":null,"abstract":" Objective: Epilepsy is a chronic non-communicable disease that can affect all ages, genders, races, and social classes with large treatment costs that vary widely between countries and regions. Perampanel is a new generation of antiepileptic drugs (AEDs), but cost-effectiveness reports are inconsistent in several countries that have conducted pharmacoeconomic evaluations. Study with the objective of systematically summarizing the evidence on the cost-effectiveness of Perampanel for the treatment of epilepsy. Methods: An exhaustive search was performed in four publication databases. Evaluation of the reporting quality of the studies using the CHEERS checklist. Results: Findings: Costs were lower in the Perampanel group than in the Lacosamide group (Perampanel 8mg/day vs. Lacosamide 400mg/day - Total cost: $2390 (12.89%), but higher than in the antiepilepsy drugs group without perampanel (Total Direct Cost: 5475 Euro and Total Indirect Cost: -5288 Euro, Total Cost: 188 Euro) and the group with recent add-on regime such as Brivaracetam (3188 Euro in total). When compared with the Lacosamide group, the Perampanel group showed increased outcomes in all three outcomes (convulsions, LY, and QALY). Similarly, the Perampanel group showed increased outcomes in all three outcomes (convulsions, LY, and QALY) compared with groups without Perampanel. Meanwhile, QALY in the Perampanel group was lower than in the Brivaracetam group (total of 0.059 QALY). Conclusions: Perampanel as an adjunct therapy for antiepilepsy drugs may be a cost-effective treatment option in the management of epilepsy. \u0000Keywords: Fycompa, perampanel, seizure, epilepsy, systematic review, cost-effective. \u0000References \u0000[1] R. S. Fisher, C. Acevedo, A. Arzimanoglou, A. Bogacz, J. H. Cross, C. E. Elger et al., ILAE Official Report: a Practical Clinical Definition of Epilepsy. Epilepsia, Vol. 55, No. 4, 2014, pp. 475-482.[2] K. M. Fiest, K. M. Sauro, S. Wiebe, S. B. Patten, C. S. Kwon, J. Dykeman, et al., Prevalence and Incidence of Epilepsy: A Systematic Review and Meta-analysis of International Studies, Neurology, Vol. 88, No. 3, 2017, pp. 296-303.[3] A. C. Meyer, T. Dua, J. Ma, S. Saxena, G. Birbeck, Global Disparities in The epilepsy Treatment Gap: a Systematic Review, Bull World Health Organ, Vol. 88, No. 4, 2010, pp. 260-266.[4] GBD, Neurology Collaborators, Global, Regional, and National Burden of Neurological Disorders, 1990-2016: a Systematic Analysis for the Global Burden of Disease Study 2016, Lancet Neurol, Vol. 18, No. 5, 2019, pp. 459-480.[5] S. Y. Chen, N. Wu, L. Boulanger, P. Sacco, Antiepileptic Drug Treatment Patterns and Economic Burden of Commercially-insured Patients with Refractory Epilepsy with Partial Onset Seizures in the United States, J Med Econ, Vol. 16, No. 2, 2013, pp. 240-248.[6] J. A. Cramer, Z. J. Wang, E. Chang, A. Powers, R. Copher, D. Cherepanov et al., Healthcare Utilization and Costs in Adults with Stable and Uncontrolled Epilepsy, Epilepsy Behav, Vol. 31,","PeriodicalId":23520,"journal":{"name":"VNU Journal of Science: Medical and Pharmaceutical Sciences","volume":"4 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78514234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-24DOI: 10.25073/2588-1132/vnumps.4388
Nguyen Hue Linh, P. Huệ, Nguyen Thi Thanh Binh, Bui Thanh Tung, V. Loi, Ng Yen, N. Hai
RNA drugs are a new group of drugs that delivers RNAs or similar structures inside the body to achieve the therapeutic effect. This is a promising direction in drug development to treat serious and rare genetic diseases more specifically and effectively. In reality, the genetic systems and protein synthesis processes of living organisms are extremely complex, so the development of RNA drugs faces many difficulties. To achieve success, many different studies have been carried out to address issues such as finding suitable RNAs, synthesizing similar RNA structures, stabilizing RNA structures, and introducing drugs into targeted cells. Since the first RNA drug was officially approved by the FDA (2004), 10 RNA drugs in total have been approved to date. Among them, two vaccines, appearing at the time when much needed support to cope with the new SARS-CoV-2 variants, were developed using mRNA technology. With these achievements, scientists can have more confidence in the possibilities of evolving a new drug group that is more specific and effective, which is RNA drugs. This review briefly introduces the group of drugs that use RNAs, RNA structural analogs, and RNA biomarkers to develop novel drugs for application in the diagnosis, prevention, and treatment of disease. Keywords: RNA drugs; mRNA; the protein; vaccines; RNA diagnostics; small molecule drugs; RNA target. References [1] U. Sahin, K. Karikó, Ö. Türeci, Mrna-Based Therapeutics-Developing A New Class of Drugs, Nature Reviews Drug Discovery, Vol. 13, No. 10, 2014, pp. 759-780.[2] T. H. Nguyen, T. M. H. Pham, M. K. Tu, Pharmacogenetics: Prospects and Issues. Journal of Pharmacy, No. 54, Vol. 456, 2014, pp. 2-6.[3] A. M. Yu, Y. H. Choi, M. J. Tu, Rna Drugs and Rna Targets for Small Molecules: Principles, Progress, and Challenges, Pharmacological Reviews, Vol. 72, No. 4, 2020, pp. 862-898.[4] M. A. Hendaus, F. A. Jomha, Mrna Vaccines for Covid-19: A Simple Explanation, Qatar Medical Journal, Vol. 2021, No. 1, 2021, pp. 1-5.[5] A. Banerji, P. G. Wickner, R. Saff, C. A. Stone Jr, L. B. Robinson, A. A. Long et al., Mrna Vaccines to Prevent Covid-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach, the Journal of Allergy and Clinical Immunology: in Practice, Vol. 9, No. 4, 2021, pp. 1423-1437.[6] https://www.Fda.Gov/Emergency-Preparedness-and-Response/Coronavirus-Disease-2019-Covid-19/Covid-19-Vaccines (accessed on: December 15th, 2021).[7] E. H. Aarntzen, G. Schreibelt, K. Bol, W. J. Lesterhuis, A. J. Croockewit, J .H. De Wilt et al., Vaccination with Mrna-Electroporated Dendritic Cells Induces Robust Tumor Antigen-Specific Cd4+ and Cd8+ T Cells Responses in Stage Iii and Iv Melanoma Patients, Clinical Cancer Research, Vol. 18, No. 19, 2012, pp. 5460-5470.[8] H. M. Phan, K. L. Vu, T. H. Nguyen, T. T. Bui, A Comprehensive Review of Vaccines Against Covid-19, VNU Journal of Science: Medical and Pharmaceutical Sciences, Vol. 37, No. 3, 2021, pp. 1-19 (in Vietnamese).[
RNA药物是一种通过在体内传递RNA或类似结构来达到治疗效果的新型药物。这是一个有希望的药物开发方向，更具体和有效地治疗严重和罕见的遗传疾病。现实中，生物体的遗传系统和蛋白质合成过程极其复杂，因此RNA药物的开发面临诸多困难。为了取得成功，人们进行了许多不同的研究，以解决诸如寻找合适的RNA，合成类似的RNA结构，稳定RNA结构以及将药物引入目标细胞等问题。自2004年第一个RNA药物被FDA正式批准以来，迄今为止总共有10个RNA药物被批准。其中，在急需支持以应对新的SARS-CoV-2变体时出现的两种疫苗是利用mRNA技术开发的。有了这些成就，科学家们可以更有信心开发出一种更特异、更有效的新药，这就是RNA药物。本文简要介绍了利用RNA、RNA结构类似物和RNA生物标志物开发用于疾病诊断、预防和治疗的新型药物。关键词:RNA药物;信使rna;蛋白质;疫苗;RNA诊断;小分子药物;RNA的目标。参考文献[1]U. Sahin, K. Karikó， Ö。引用本文:陈志强，基于mrna的治疗方法——开发一类新的药物，《自然评论》，2014年第10期，第759-780页阮廷辉，范廷辉，杜明强，药物遗传学:展望与问题。中国药学杂志，2014年第54期，第456卷，第2-6页余亚明，蔡玉辉，杜明军，小分子Rna药物和Rna靶点:原理，进展和挑战，药理学评论，Vol. 72, No. 4, 2020, pp. 862-898M. A. Hendaus, F. A. Jomha，新冠病毒Mrna疫苗:一个简单的解释，卡塔尔医学杂志，Vol. 2021, No. 1, 2021, pp. 1-5A. Banerji, P. G. Wickner, R. Saff, C. A. Stone Jr, L. B. Robinson, A. A. Long等。Mrna疫苗预防Covid-19疾病和报告的过敏反应:目前的证据和建议的方法，过敏和临床免疫学杂志:在实践中，Vol. 9, No. 4, 2021, pp. 1423-1437。[6] https://www.Fda.Gov/Emergency-Preparedness-and-Response/Coronavirus-Disease-2019-Covid-19/Covid-19-Vaccines(访问时间:2021年12月15日)E. H. Aarntzen, G. Schreibelt, K. Bol, W. J. Lesterhuis, A. J. Croockewit, J. h。De Wilt等，mrna电穿孔树突状细胞免疫诱导肿瘤抗原特异性Cd4+和Cd8+ T细胞在Iii期和Iv期黑色素瘤患者中的应答，临床癌症研究，Vol. 18, No. 19, 2012, pp. 5460-5470潘洪明，吴国良，阮廷辉，裴廷涛，新型冠状病毒疫苗研究进展，中华医学杂志，第37卷，第3期，2021,pp. 1-19(越南文)杨建军，杨建军，杨建军，Mrna疫苗:疫苗学的新时代，《自然评论》，2018年第4期，第261-279页温刚，周涛，顾伟，血液循环Rna作为液体活检生物标志物的潜力。蛋白质与细胞，Vol. 12, No. 12, 2021, pp. 911-946李建军，李建军，李建军，李建军。鼻咽癌患者预后的meta分析及预后评价。Plos One, Vol. 14, No. 2, 2019, pp. 1-18王峰、王志强、王志强，Rna疗法的兴起，《新药物发现》，Vol. 19, No. 7, 2020, pp. 441-442王志强，王志强，Dna和Rna靶向治疗在亨廷顿舞蹈病中的应用，中华医学杂志，2017，第10期，pp. 837-847韩辉，Rna干扰基因敲低基因表达的研究，中国生物医学工程学报，2018,pp. 391 - 391刘建军，刘建军，刘建军，刘建军等，罕见遗传疾病患者自定义寡核苷酸治疗的研究进展，中华医学杂志，2019，第17期，pp. 1644-1652美国食品和药物管理局批准首个基于靶向rna的治疗罕见疾病的药物，Silver Spring (Md): Usfda, 2018. b[17]E. Sardh, P. Harper, M. Balwani, P. Stein, D. Rees, D. M. Bissel等，Rna干扰治疗急性间歇性卟啉症的1期试验，新英国医学杂志，Vol. 380, No. 6, 2019, pp. 549-558李志强，基于sirna的肿瘤治疗方法，《肿瘤基因治疗》Vol. 13 No. 9, 2006, pp. 819-829陈晓明，陈晓明，陈晓明，陈晓明等。rna结合蛋白Larp1在卵巢癌中的表达及其调控作用，中国生物医学工程学报，2016,No. 3, pp. 1227-1246V. Iadevaia, M. D. Wouters, A. Kanitz, A. M. M. González, E. E. Laing, A. P。 Gerber，串联Rna分离揭示顺铂处理细胞中Cdkn1b/P27 Kip1 3'utrs上Rna结合蛋白的功能重排，Rna生物学，Vol. 17, No. 1, 2020, pp. 33-46裴廷涛，潘金生，范明辉，阮廷辉，姜黄素聚乙二醇化及其应用前景，中国生物医学工程学报，Vol. 32, No. 1, 2016, pp 1-11。
{"title":"RNA Drugs","authors":"Nguyen Hue Linh, P. Huệ, Nguyen Thi Thanh Binh, Bui Thanh Tung, V. Loi, Ng Yen, N. Hai","doi":"10.25073/2588-1132/vnumps.4388","DOIUrl":"https://doi.org/10.25073/2588-1132/vnumps.4388","url":null,"abstract":"RNA drugs are a new group of drugs that delivers RNAs or similar structures inside the body to achieve the therapeutic effect. This is a promising direction in drug development to treat serious and rare genetic diseases more specifically and effectively. In reality, the genetic systems and protein synthesis processes of living organisms are extremely complex, so the development of RNA drugs faces many difficulties. To achieve success, many different studies have been carried out to address issues such as finding suitable RNAs, synthesizing similar RNA structures, stabilizing RNA structures, and introducing drugs into targeted cells. Since the first RNA drug was officially approved by the FDA (2004), 10 RNA drugs in total have been approved to date. Among them, two vaccines, appearing at the time when much needed support to cope with the new SARS-CoV-2 variants, were developed using mRNA technology. With these achievements, scientists can have more confidence in the possibilities of evolving a new drug group that is more specific and effective, which is RNA drugs. This review briefly introduces the group of drugs that use RNAs, RNA structural analogs, and RNA biomarkers to develop novel drugs for application in the diagnosis, prevention, and treatment of disease. \u0000Keywords: \u0000RNA drugs; mRNA; the protein; vaccines; RNA diagnostics; small molecule drugs; RNA target. \u0000References \u0000[1] U. Sahin, K. Karikó, Ö. Türeci, Mrna-Based Therapeutics-Developing A New Class of Drugs, Nature Reviews Drug Discovery, Vol. 13, No. 10, 2014, pp. 759-780.[2] T. H. Nguyen, T. M. H. Pham, M. K. Tu, Pharmacogenetics: Prospects and Issues. Journal of Pharmacy, No. 54, Vol. 456, 2014, pp. 2-6.[3] A. M. Yu, Y. H. Choi, M. J. Tu, Rna Drugs and Rna Targets for Small Molecules: Principles, Progress, and Challenges, Pharmacological Reviews, Vol. 72, No. 4, 2020, pp. 862-898.[4] M. A. Hendaus, F. A. Jomha, Mrna Vaccines for Covid-19: A Simple Explanation, Qatar Medical Journal, Vol. 2021, No. 1, 2021, pp. 1-5.[5] A. Banerji, P. G. Wickner, R. Saff, C. A. Stone Jr, L. B. Robinson, A. A. Long et al., Mrna Vaccines to Prevent Covid-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach, the Journal of Allergy and Clinical Immunology: in Practice, Vol. 9, No. 4, 2021, pp. 1423-1437.[6] https://www.Fda.Gov/Emergency-Preparedness-and-Response/Coronavirus-Disease-2019-Covid-19/Covid-19-Vaccines (accessed on: December 15th, 2021).[7] E. H. Aarntzen, G. Schreibelt, K. Bol, W. J. Lesterhuis, A. J. Croockewit, J .H. De Wilt et al., Vaccination with Mrna-Electroporated Dendritic Cells Induces Robust Tumor Antigen-Specific Cd4+ and Cd8+ T Cells Responses in Stage Iii and Iv Melanoma Patients, Clinical Cancer Research, Vol. 18, No. 19, 2012, pp. 5460-5470.[8] H. M. Phan, K. L. Vu, T. H. Nguyen, T. T. Bui, A Comprehensive Review of Vaccines Against Covid-19, VNU Journal of Science: Medical and Pharmaceutical Sciences, Vol. 37, No. 3, 2021, pp. 1-19 (in Vietnamese).[","PeriodicalId":23520,"journal":{"name":"VNU Journal of Science: Medical and Pharmaceutical Sciences","volume":"74 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73430225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-24DOI: 10.25073/2588-1132/vnumps.4341
D. Ngoc, Ho Thi Nhung, Tran Cong Hoan
A study of 55 patients with lumbar disc herniation who were taken MRI and surgery at hospital E from January 2019 to December 2019. Results: The mean age was 58.96 ± 16.4, the female/male ratio was 1.12/1. People doing heavy work had a higher risk of disc herniation than those doing light work (63.7%). Common symptoms: lumbar pain (100%), sciatica pain, pain with mechanical properties (85.45%), limited spinal movement (90.91%), Lasègue sign (+) (74.55%), bell sign (+) (54.55%); signs of nerve root damage: sensory disturbances 72.73%, movement disorders 50.91%. Clinical lesions were common in L5 (65.45%) and S1 (45.45%) roots. Hernias were common at L4/5 (81.8%) and L5/S1 (70.9%). The degree of hernia was mainly bulge and hernia, accounting for 60% and 52.73%, respectively. 98.18% herniated to the back, central hernia accounted for the highest rate (41.82%). The rate of nerve root compression detected on MR is 90.91%. Evaluation of nerve root damage in clinical and magnetic resonance had high concordance in L5 and S1 roots (98.17% and 100%, respectively). Conclusion: MRI helps in early, accurate diagnosis and treatment orientation of lumbar disc herniation. Keywords: Disc herniation, MRI lumbar spine, lumbar pain. References [1] R. J. Gardocki, A. L. Park, Lower Back Pain and Disorders of Intervertebral Discs, Campbell's Operative Orthopaedics, 12th ed, Elsevier Mosby, 2013:chap 42.[2] N. V. Chuong et al., Research on Lumbar Disc Herniation at Department - Department of Internal Neurology, Hospital 103 - Military Medical Academy, Journal of Military Medicine, Vol. 3, 2015, pp. 5 - 16 (in Vietnamese).[3] S. Lee, J. H. Kang, U. Srikantha et al., Extral Foraminal Compression of the L5 Nerve Root at the Lumbosacral Junction: Clinical Analysis, Decompression Technique, and Outcome, Journal Neurosurgery Spine, Vol. 24, No. 1, 2014, pp. 1-9, https://doi.org/10.3171/2013.12.spine12629.[4] S. Eicker, S. Rhee, H. Steiger et al., Transtubular Microsurgical Approach to Treating Extra Foraminal Lumbar Disc Herniations, Neurosurgery Focus, Vol. 35, No. 2E1, 2013, pp. 1-6, https://doi.org/10.3171/2013.4.focus13126. [5] H. M. Cuong, Research on the Diagnosis and Surgical Treatment of Disc Herniation in the Lumbar Spine and Side Deviation by Bone Window Opening Method, Master's Thesis of Medicine, Hanoi Medical University, 2010 (in Vietnamese).[6] J. D. Lurie, T. D. Tosteson, A. N. Tostenson et al., Surgical Versus Non-operative Treatment for Lumbar Disc Herniation: Eight-year Results for the Spine Patient Outcomes Research Trial, Spine, Vol. 39, No. 1, 2014, pp. 3-16, https://dx.doi.org/10.1097%2FBRS.0000000000000088.[7] M. R. Konieczny, R. Jeremia, M. Post et al., Signal Intensity of Lumbar Disc Herniations: Correlation With Age of Herniation for Extrusion, Protrusion, and Sequestration, Int J Spine Surg. Vol. 14, No. 1, 2020, pp. 102–107, https://doi.org/10.14444/7014.[8] M. H. Daghighi, M. Pouriesa, M. Maleki et al., Migration Patterns of Herniated Disc
对2019年1月至2019年12月在E医院行MRI和手术治疗的55例腰椎间盘突出症患者的研究。结果:患者平均年龄58.96±16.4岁，男女比例1.12/1。从事重体力劳动的人患椎间盘突出的风险高于从事轻体力劳动的人(63.7%)。常见症状:腰痛(100%)、坐骨神经痛、机械性疼痛(85.45%)、脊柱活动受限(90.91%)、las征(+)(74.55%)、钟征(+)(54.55%);神经根损伤征象:感觉障碍72.73%，运动障碍50.91%。临床病变多见于L5根(65.45%)和S1根(45.45%)。疝常见于L4/5(81.8%)和L5/S1(70.9%)。疝的程度以突出和疝为主，分别占60%和52.73%。背部疝占98.18%，中央疝占41.82%。MR显示神经根受压率为90.91%。临床与磁共振评价神经根损伤在L5和S1根上的一致性较高(分别为98.17%和100%)。结论:MRI有助于腰椎间盘突出症的早期、准确诊断和治疗定位。关键词:椎间盘突出，MRI腰椎，腰痛。[1] R. J. Gardocki, A. L. Park，下背部疼痛和椎间盘疾病，Campbell's surgical orthopotics，第12版，Elsevier Mosby, 2013:第42章。[2]钟n . V.等，军医103医院内科-神经内科腰椎间盘突出症的研究，军事医学杂志，2015年第3卷，第5 - 16页。[3]S. Lee, J. H. Kang, U. Srikantha等，腰骶交界处L5神经根的椎间孔外压迫:[4]李志强，李志强，李志强等，经突突显微外科入路治疗椎间孔外椎间盘突出症，神经外科杂志，2013，第35卷，第2期，第1-6页，https://doi.org/10.3171/2013.4.focus13126。[5]张洪明，骨窗打开法治疗腰椎间盘突出及侧偏的研究，河内医科大学医学硕士论文，2010 [6]J. D. Lurie, T. D. Tosteson, A. N. Tostenson等，手术与非手术治疗腰椎间盘突出症:8年脊柱患者预后研究的结果，脊柱，Vol. 39, No. 1, 2014, pp. 3-16, https://dx.doi.org/10.1097%2FBRS.0000000000000088.[7] M. R. Konieczny, R. Jeremia, M. Post等，腰椎间盘突出症的信号强度:[8]张晓明，张晓明，张晓明，等。椎间盘突出碎片移位模式与年龄的相关性分析。中华脊柱外科杂志，2020，第1期，pp. 102-107, https://doi.org/10.14444/7014.[8][9]王晓明，王晓明，王晓明，青少年腰椎间盘突出症的临床研究，中华脊柱杂志，2014年第9期，第70-1977页，https://doi.org/10.1016/j.spinee.2013.11.056.[9]影响,诊断和治疗,J . Musculoskelet Rehabil, 30卷,2号,2017年,页347 - 352,https://doi.org/10.3233/bmr - 160572。[10]r·g·梅农m . v . w . Zibetti m . Pendola et al .,内部动态三维测量腰椎的椎间盘的压力和机械负荷Golden-Angle径向稀疏Parallel-Magnetic磁共振成像,成像因素J增效,54卷,2号,2021年,页486 - 496,https://doi.org/10.1002/jmri.27591。
{"title":"Features of Clinical and Magnetic Resonance Imaging of Lumbar Disc Herniation","authors":"D. Ngoc, Ho Thi Nhung, Tran Cong Hoan","doi":"10.25073/2588-1132/vnumps.4341","DOIUrl":"https://doi.org/10.25073/2588-1132/vnumps.4341","url":null,"abstract":"A study of 55 patients with lumbar disc herniation who were taken MRI and surgery at hospital E from January 2019 to December 2019. Results: The mean age was 58.96 ± 16.4, the female/male ratio was 1.12/1. People doing heavy work had a higher risk of disc herniation than those doing light work (63.7%). Common symptoms: lumbar pain (100%), sciatica pain, pain with mechanical properties (85.45%), limited spinal movement (90.91%), Lasègue sign (+) (74.55%), bell sign (+) (54.55%); signs of nerve root damage: sensory disturbances 72.73%, movement disorders 50.91%. Clinical lesions were common in L5 (65.45%) and S1 (45.45%) roots. Hernias were common at L4/5 (81.8%) and L5/S1 (70.9%). The degree of hernia was mainly bulge and hernia, accounting for 60% and 52.73%, respectively. 98.18% herniated to the back, central hernia accounted for the highest rate (41.82%). The rate of nerve root compression detected on MR is 90.91%. Evaluation of nerve root damage in clinical and magnetic resonance had high concordance in L5 and S1 roots (98.17% and 100%, respectively). Conclusion: MRI helps in early, accurate diagnosis and treatment orientation of lumbar disc herniation. \u0000Keywords: Disc herniation, MRI lumbar spine, lumbar pain. \u0000References \u0000[1] R. J. Gardocki, A. L. Park, Lower Back Pain and Disorders of Intervertebral Discs, Campbell's Operative Orthopaedics, 12th ed, Elsevier Mosby, 2013:chap 42.[2] N. V. Chuong et al., Research on Lumbar Disc Herniation at Department - Department of Internal Neurology, Hospital 103 - Military Medical Academy, Journal of Military Medicine, Vol. 3, 2015, pp. 5 - 16 (in Vietnamese).[3] S. Lee, J. H. Kang, U. Srikantha et al., Extral Foraminal Compression of the L5 Nerve Root at the Lumbosacral Junction: Clinical Analysis, Decompression Technique, and Outcome, Journal Neurosurgery Spine, Vol. 24, No. 1, 2014, pp. 1-9, https://doi.org/10.3171/2013.12.spine12629.[4] S. Eicker, S. Rhee, H. Steiger et al., Transtubular Microsurgical Approach to Treating Extra Foraminal Lumbar Disc Herniations, Neurosurgery Focus, Vol. 35, No. 2E1, 2013, pp. 1-6, https://doi.org/10.3171/2013.4.focus13126. \u0000[5] H. M. Cuong, Research on the Diagnosis and Surgical Treatment of Disc Herniation in the Lumbar Spine and Side Deviation by Bone Window Opening Method, Master's Thesis of Medicine, Hanoi Medical University, 2010 \u0000(in Vietnamese).[6] J. D. Lurie, T. D. Tosteson, A. N. Tostenson et al., Surgical Versus Non-operative Treatment for Lumbar Disc Herniation: Eight-year Results for the Spine Patient Outcomes Research Trial, Spine, Vol. 39, No. 1, 2014, pp. 3-16, https://dx.doi.org/10.1097%2FBRS.0000000000000088.[7] M. R. Konieczny, R. Jeremia, M. Post et al., Signal Intensity of Lumbar Disc Herniations: Correlation With Age of Herniation for Extrusion, Protrusion, and Sequestration, Int J Spine Surg. Vol. 14, No. 1, 2020, pp. 102–107, https://doi.org/10.14444/7014.[8] M. H. Daghighi, M. Pouriesa, M. Maleki et al., Migration Patterns of Herniated Disc ","PeriodicalId":23520,"journal":{"name":"VNU Journal of Science: Medical and Pharmaceutical Sciences","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74255973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：